FDA warning practice
Montelukast: match the boxed warning to the indication and symptoms
An older leaflet can miss a warning that changes counseling. FDA strengthened montelukast warnings in 2020 because of serious mental-health effects and restricted allergic-rhinitis use. That warning should be checked directly rather than inferred from a stale generic label.
Sources checked October 10, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Read the newer warning rather than a convenient older label
FDA required a boxed warning about serious neuropsychiatric events, including suicidal thoughts or actions, and advises discussing benefits and risks before prescribing. A fetched older 2017 label is not an adequate stopping point when the 2020 FDA warning supplies materially different guidance.
This page uses the FDA communication for that reason. It does not claim a new October 2026 alert. Source age and update history matter: an old product page can still be online, and its existence does not prove it contains the current warning. Recover the actual source before reassuring a patient that no boxed warning exists.
Apply the indication-specific restriction
For allergic rhinitis, FDA says montelukast should be reserved for patients with inadequate response or intolerance to alternative therapies. A request for convenient once-daily allergy relief does not by itself establish that criterion. Recover which alternatives were tried and what happened.
For asthma, FDA advises considering benefit and risk of mental-health effects before prescribing. Do not turn the allergic-rhinitis restriction into an unsupported claim that the medicine is never used in asthma. Indication changes the benefit-risk question, while the need for counseling remains.
Do not require a psychiatric history to take symptoms seriously
FDA says serious effects have occurred in people with and without a history of mental illness. A patient with no prior diagnosis can still report a relevant new mood or behavior change. The history informs assessment but cannot rule out the warning.
FDA advises patients to stop montelukast and contact a healthcare professional immediately if behavior or mood-related changes occur. Reports include events during treatment and some after discontinuation. Do not promise that symptoms must disappear immediately after stopping or recommend waiting weeks simply because allergy symptoms improved.
Build a specific counseling and follow-up plan
Ask about what changed, when symptoms began, medicine use and immediate safety concerns. Urgent mental-health or self-harm concerns need appropriate emergency assessment. A medication review must not delay that care while debating whether the drug is definitely the cause.
This lesson does not diagnose a drug reaction or choose a replacement allergy or asthma medicine. It teaches the FDA stopping/contact guidance and the indication-specific decision. A complete plan also addresses respiratory treatment continuity through the clinical team rather than leaving a patient with no understanding of what to do next.
A worked case
A patient prescribed montelukast as their first allergic-rhinitis treatment develops vivid dreams and new agitation. They have no psychiatric history and bring a 2017 leaflet. A colleague recommends continuing because the allergy improved. Which source and findings matter?
- Use the 2020 FDA boxed-warning communication, not the older leaflet as final authority.
- First-line convenience does not establish inadequate response or intolerance to alternatives.
- No psychiatric history does not exclude events; apply stopping and immediate-contact guidance and assess current safety.
Answer: The indication and new symptoms need review under the strengthened warning. Symptom benefit does not cancel the safety assessment.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Does no previous mental illness exclude the warning?
No.
2. Is montelukast the unrestricted first choice for mild allergic rhinitis under FDA's advice?
No. Reserve it for inadequate response or intolerance to alternatives.
3. Does stopping guarantee every reported symptom resolves immediately?
No. FDA notes reports after discontinuation too.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.